People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Both Mounjaro and Zepbound are produced by the pharmaceutical company Eli Lilly. Now, a new study funded ... were taking Mounjaro as an off-label treatment for weight management “at the ...

Lilly claims the single-dose versions ... In a statement, Ro said it will make Zepbound available as a treatment option with an on-label prescription from a Ro-affiliated provider that will ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study ... Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...